Boardroom Alpha
Start trial
10-Q primary document
DSGN · Quarterly Report (Form 10-Q) · Filed August 3, 2026

Design Therapeutics Inc — 10-Q exhibit

dsgn-ex10_1.htm
Design Therapeutics Inc on Boardroom Alpha
EX-10.1

Exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

WARF Agreement No. [***]

FIRST AMENDMENT TO HUMAN THERAPEUTICS EXCLUSIVE LICENSE AGREEMENT

This First Amendment (“Amendment”) made effective the 1st day of May, 2026, is by and between the Wisconsin Alumni Research Foundation (“WARF”), a nonstock, nonprofit Wisconsin corporation, and Design Therapeutics, Inc. (“Licensee”), a corporation organized and existing under the laws of Delaware.

WITNESSETH

WHEREAS, WARF and Licensee entered into a Human Therapeutics Exclusive License Agreement made effective February 20, 2019 (the “Agreement”); and

WHEREAS, WARF and Licensee would each like to amend the Agreement to [***].

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth below and in the Agreement, the parties covenant and agree as follows:

1.
Section 3C (ii) is hereby deleted in its entirety and replaced with the following:

[***]

2.
Capitalized terms used herein and not otherwise defined shall have the meaning set forth in the Agreement. Except as otherwise provided in this Amendment, all terms and conditions previously set forth in the Agreement shall remain in effect as set forth therein. In the event that this Amendment and the Agreement are inconsistent, the terms and provisions of this Amendment shall supersede the terms and provisions of the Agreement, but only to the extent necessary to satisfy the purpose of this Amendment. Each party hereto represents to the other that it has the full authority to execute, deliver and perform this Amendment in accordance with its terms. The persons signing on behalf of WARF and Licensee hereby warrant and represent that they have authority to execute this Amendment on behalf of the party for whom they have signed. This Amendment may be executed in one or more counterparts by the parties by signature of a person having authority to bind the party, each of which when executed and delivered by facsimile, electronic transmission, or by mail delivery, will be an original and all of which will constitute but one and the same Amendment. The parties agree this Amendment may be electronically signed and that the electronic signatures appearing on this Amendment are the same as handwritten signatures for the purposes of validity, enforceability, and admissibility.

 

Design Tx – [***]

 

Page 1 of 2

 

Wisconsin Alumni Research Foundation

 

***Certain Confidential Information Omitted

 

WARF Agreement No. [***]

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment on the dates indicated below.

 

 

WISCONSIN ALUMNI RESEARCH FOUNDATION

 

 

 

 

 

 

 

 

 

 

 

By:

 

/s/ Michael Falk

 

Date:

 

5/1/2026

 

 

Michael Falk, Chief Intellectual Property & Licensing Officer

 

 

 

 

 

 

 

 

 

 

 

 

DESIGN THERAPEUTICS, INC.

 

 

 

 

 

 

 

 

 

 

 

By:

 

/s/ Pratik Shah

 

Date:

 

5/1/2026

 

 

 

 

 

 

 

 

 

Pratik Shah, Ph.D. – President, CEO, and Chairperson

 

 

 

 

 

 

Design Tx – [***]

 

Page 2 of 2

 

Wisconsin Alumni Research Foundation

 

***Certain Confidential Information Omitted

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer